Successful Treatment of Sarcoidosis
Authors: Yousaf Ali, Elliot Perlman
Journal: Annals of Internal Medicine (2004)

Letters1 June 2004Successful Treatment of SarcoidosisYousaf Ali, MD and Elliot Perlman, MDYousaf Ali, MDFrom Brown University, Providence, RI 02912.Search for more papers by this author and Elliot Perlman, MDFrom Brown University, Providence, RI 02912.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-11-200406010-00028-w1 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Ocular inflammation is a prominent manifestation of several autoimmune diseases. Although anti–tumor necrosis factor (TNF) therapy has been successfully used to treat uveitis associated with the HLA-B27 gene, the Behçet syndrome (1), and refractory idiopathic uveitis (2), its effect in sarcoid uveitis are unknown. We describe successful treatment using intravenous infliximab, a human-murine chimeric monoclonal antibody directed against TNF in a patient with sarcoid-related uveitis.The patient presented with anterior uveitis, Bell palsy, and low-grade fever. Sarcoidosis was diagnosed on the basis of stage 1 bilateral hilar lymphadenopathy and an elevated angiotensin-converting enzyme level. Ocular examination revealed ...References1. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342-6. [PMID: 12466181] CrossrefMedlineGoogle Scholar2. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-53. [PMID: 12867408] CrossrefMedlineGoogle Scholar3. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-4. [PMID: 11354550] MedlineGoogle Scholar4. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al . Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124:177-85. [PMID: 12853521] CrossrefMedlineGoogle Scholar5. Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, et al . Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-8. [PMID: 8843907] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Brown University, Providence, RI 02912. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: Successful Treatment of Refractory Sarcoidosis-Associated Uveitis with Infliximab Metrics Cited byMonitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant RecipientsAgents anti-TNFα et sarcoïdoseOcular Manifestations of SarcoidosisExpression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosisDifferential Effectiveness of Etanercept and Infliximab in the Treatment of Ocular InflammationTreatment of therapy-resistant sarcoidosis with adalimumabNonsteroidal Therapy of SarcoidosisIsolated sarcoid granulomatous interstitial nephritis responding to infliximab therapyCorrection: Successful Treatment of Refractory Sarcoidosis-Associated Uveitis with Infliximab 1 June 2004Volume 140, Issue 11Page: W-48KeywordsDrugsMethotrexateNecrosisParalysisPathogenesisPatientsSarcoidosisTumor necrosis factorUveitisVision ePublished: 1 June 2004 Issue Published: 1 June 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...